Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
QuintilesIMS
Julphar
Healthtrust
Daiichi Sankyo
Chinese Patent Office
Express Scripts
Federal Trade Commission
Chubb

Generated: June 25, 2018

DrugPatentWatch Database Preview

ILUVIEN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Iluvien patents expire, and when can generic versions of Iluvien launch?

Iluvien is a drug marketed by Alimera Sciences Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and eighty-three patent family members in twenty-six countries.

The generic ingredient in ILUVIEN is fluocinolone acetonide. There are twelve drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the fluocinolone acetonide profile page.
Summary for ILUVIEN
Drug patent expirations by year for ILUVIEN
Pharmacology for ILUVIEN
Medical Subject Heading (MeSH) Categories for ILUVIEN
Synonyms for ILUVIEN
(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0;{2,9}.0;{4,8}.0;{13,18}]icosa-14,17-dien-16-one
(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-DIFLUORO-11-HYDROXY-8-(2-HYDROXYACETYL)-6,6,9,13-TETRAMETHYL-5,7-DIOXAPENTACYCLO[10.8.0.0(2),?.0?,?.0(1)(3),(1)?]ICOSA-14,17-DIEN-16-ONE
(2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[
(2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one
(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
010F525
0CD5FD6S2M
2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one
4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide
6.alpha.-Fluorotriamcinolone acetonide
6.Alpha., 9.alpha.-Difluoro-16.alpha.-h
6.alpha., 9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide
6.alpha.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone
6.alpha.,17-acetonide
6.Alpha.,9-Difluoro
6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone
6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide
6|A,9|A-Difluoro-11|A,16|A,17|A,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-acetonide
67-73-2
6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide
6alpha-Fluorotriamcinolone acetonide
6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone
6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide
6alpha,9alpha-difluoro-11beta,21-dihydroxy-16alpha-17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione;
6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide
AB00383017_11
AB00383017-10
AB1010906
AC-429
AC1L1M1L
AC1Q6ACL
Acetonida de fluocinolona
Acetonida de fluocinolona [INN-Spanish]
Acetonide de fluocinolone
Acetonide de fluocinolone [INN-French]
acetonido de fluocinolona
ACN-043362
AKOS015963144
ARONIS24561
AS-13690
BC214761
C-22503
C24H30F2O6
Capex
CAS-67-73-2
CC-28473
CCG-221165
CCRIS 3250
CHEBI:31623
CHEMBL989
component of Neo-Synalar
Coriphate
Cortiplastol
CS-2519
D01825
D02QJH
DB00591
Derma-smoothe/fs
Dermalar
Dermatin (steroid)
difluoro-hydroxy-(2-hydroxyacetyl)-tetramethyl-[?]one
DSSTox_CID_20674
DSSTox_GSID_40674
DSSTox_RID_79533
DTXSID0040674
EBD4852
EINECS 200-668-5
F0657
FEBLZLNTKCEFIT-VSXGLTOVSA-N
Flucinar
flucinolone
Flucort
Flucort-N
Flucort-N (TN)
Fluocet
Fluocet (TN)
Fluocinolon acetonid
Fluocinolonacetonid
Fluocinolonacetonidum
Fluocinolone (Acetonide)
Fluocinolone 16,17-acetonide
FLUOCINOLONE ACETONIDE
Fluocinolone acetonide (Flucort-N)
Fluocinolone acetonide (JP15/USP/INN)
Fluocinolone acetonide (JP17/USP/INN)
Fluocinolone acetonide [DCIT]
Fluocinolone acetonide [USAN:INN:JAN]
Fluocinolone acetonide [USAN:USP:INN:JAN]
fluocinolone acetonide dihydrate
Fluocinolone acetonide for peak identification, European Pharmacopoeia (EP) Reference Standard
Fluocinolone acetonide for system suitability, European Pharmacopoeia (EP) Reference Standard
Fluocinolone acetonide intravitreal implant
fluocinolone acetonide oil
Fluocinolone acetonide, analytical standard
Fluocinolone acetonide, European Pharmacopoeia (EP) Reference Standard
Fluocinolone Acetonide, pharmaceutical secondary standard; traceable to USP, PhEur and BP
Fluocinolone acetonide, United States Pharmacopeia (USP) Reference Standard
Fluocinolone acetonide(Flucort-N)
Fluocinoloneacetonide
Fluocinoloni acetonidum
Fluocinoloni acetonidum [INN-Latin]
Fluonid
Fluortriamcinolone Acetonide
Fluotrex
Fluovitif
Flupollon
Fluzon [Steroid]
Fs Shampoo
GTPL7077
HMS2090I14
HMS2230D13
HMS3259G12
HSDB 3083
HY-B0415
J10113
Jellin
Localyn
Localyn Syntex
LS-118443
Medidur
MFCD00010525
MLS000028545
MLS001076276
MolPort-002-528-328
NC00562
NCGC00021301-04
NCGC00021301-06
NCGC00255654-01
NCI60_042042
Neo-Synalar
NSC 92339
NSC-92339
NSC92339
Omniderm
Opera_ID_1295
Percutina
PL000407
Pregna-1,20-dione, 6,9-difluoro-11,12-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-
Pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)-, (6.alpha.,11.beta.,16.alpha.)-
Pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-
Pregna-1,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,12-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6-alpha,11-beta,16-alpha)-
Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-
Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI)
Prodermin
Radiocin
Retisert
Retisert (TN)
RL04590
RS 1401AT
RS-1401 AT
s2470
SCHEMBL4795
Sinalar
SMR000058329
SR-01000000109
SR-01000000109-2
STOCK1N-55828
Synalar
Synalar (TN)
Synalar-HP
Synamol
Synandone
Synandrone
Synemol
Synotic
Synsac
Tefunote
Tox21_110869
Tox21_110869_1
Tox21_302364
UNII-0CD5FD6S2M
W-104704
WLN: T F5 E5 B666 GO IO RV AHTTTT&J A BF CQ E FVIQ H H OF -A&BHO -B&ACEF
ydroxyprednisolone 16,17-acetonide
ZINC3977981

US Patents and Regulatory Information for ILUVIEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for ILUVIEN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,815,284 Bioerodible sustained release drug delivery systems ➤ Sign Up
9,566,336 In situ gelling drug delivery system ➤ Sign Up
7,439,249 Inhibitors of phosphatases ➤ Sign Up
8,574,659 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for ILUVIEN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014000063 Germany ➤ Sign Up PRODUCT NAME: FLUOCINOLONACETONID; NAT. REGISTRATION NO/DATE: 82809.00.00 20120720; FIRST REGISTRATION: GB PL 27813/0001 20120504
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
UBS
Fish and Richardson
Argus Health
QuintilesIMS
Cantor Fitzgerald
Federal Trade Commission
Cerilliant
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.